HyNOVA - Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer

This study is investigating the safety of administering heated (42 degrees Celsius) versus normal temperature (37 degrees Celsius) chemotherapy during surgery for ovarian cancer patients.

Category
Trial Status
Recruiting
Trial Phase
Phase 2 Drug Trial
ERM Project ID
77543
Trial contact details
Contact Person
Claire Jackson
What you need to know

Who can take part?

You may be eligible for this trial if you are a female aged 18-75 years who has been diagnosed with primary stage III epithelial ovarian, fallopian tube or peritoneal cancer with disease that is limited to the abdominal cavity. You must have had 3-4 cycles of pre-operative platinum-based chemotherapy and be fit for surgery.

What is involved for you?

Participants will receive cisplatin chemotherapy administered intraperitoneally to the abdominal cavity during surgery. They will randomly be allocated to either a hyperthermic arm, who will receive the chemotherapy drug heated to 42 degrees Celsius, or a normothermic arm who will receive the drug at normal body temperature of 37 degrees Celsius. Follow-up information about adverse events, quality of life and disease outcomes will be collected following the surgery. Extra research bloods and tissue are also taken during the trial. You will be followed up at your clinic appointments for the first 2 years post surgery.

Trial dates

November 2022 - December 2024

All research clinical trials news

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.

29

Feb

Highlighting Mater Research’s year of achievements: 2023 Annual Report

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.

27

Oct

Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.

23

May

Mater launches trial of Australian-first flu vaccine

Displaying results 1-3 (of 18)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|